Related Experiment Video
Updated: Aug 9, 2026
07:40
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Update on clinically significant drug interactions in dermatology
1Department of Dermatology, Schusterman Health Sciences Center, The University of Oklahoma, College of Medicine-Tulsa, Tulsa, Oklahoma, USA. vpbmd@aol.com
Journal of the American Academy of Dermatology
|March 21, 2006
Summary
Many drug interactions (DIs) are not clinically significant, yet current systems miss dangerous ones. This review focuses on significant DIs for dermatologists, offering a logical approach to understanding them.
Area of Science:
- Pharmacology
- Dermatology
- Clinical Toxicology
Background:
- Thousands of drug interactions (DIs) are documented, but a small fraction possess clinical significance.
- Existing computational and manual systems for DIs exhibit limitations, failing to identify a substantial portion of dangerous interactions.
- Dermatologists frequently manage patients on systemic medications, necessitating awareness of critical drug interactions.
Purpose of the Study:
- To provide an updated review of clinically significant drug interactions relevant to dermatological practice.
- To highlight systemic drugs posing risks for dermatologists.
- To introduce a systematic, evidence-based approach for understanding DIs, moving beyond rote memorization.
Main Methods:
- Review of literature and databases for drug interactions up to September 2005.
- Focus on systemic drugs commonly used in dermatology.
- Analysis of key aspects of DIs to facilitate a logical understanding.
Main Results:
- Only approximately 10% of documented drug interactions are clinically significant.
- Current DI detection systems may fail to identify up to one-third of dangerous interactions.
- The review identifies specific systemic drugs and interaction patterns crucial for dermatologists.
Conclusions:
- A critical evaluation of drug interactions is essential, as many documented interactions lack clinical relevance.
- Healthcare providers, particularly dermatologists, must be aware of the limitations in current DI detection systems.
- Adopting a systematic, evidence-based approach to understanding drug interactions enhances patient safety and clinical decision-making.
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.